[
  {
    "ts": null,
    "headline": "ABBV vs. MRK: An Oncology-Immunology Showdown for Investors",
    "summary": "ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to power earnings into 2029 bode well.",
    "url": "https://finnhub.io/api/news?id=dc8e1aee0d5f2a73f309f6897172ff20bf593c3492013eb33d815d6e66f051c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769101380,
      "headline": "ABBV vs. MRK: An Oncology-Immunology Showdown for Investors",
      "id": 138206816,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to power earnings into 2029 bode well.",
      "url": "https://finnhub.io/api/news?id=dc8e1aee0d5f2a73f309f6897172ff20bf593c3492013eb33d815d6e66f051c6"
    }
  },
  {
    "ts": null,
    "headline": "Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio",
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
    "url": "https://finnhub.io/api/news?id=570b657cb6bc595276c9f148332ab0b79992675fcdd9507a1366f62658bf2594",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769100302,
      "headline": "Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio",
      "id": 138206840,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
      "url": "https://finnhub.io/api/news?id=570b657cb6bc595276c9f148332ab0b79992675fcdd9507a1366f62658bf2594"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Stock Slumps. The Nutrition Business Is a Drag on Earnings.",
    "summary": "Shares of  Abbott Laboratories  tumbled Thursday after the medical devices maker posted fourth-quarter earnings and sales that underwhelmed Wall Street.  The company said it expects full-year adjusted earnings in the range of $5.55 to $5.80 a share.  Abbott also is targeting full-year organic sales growth of between 6.5% to 7.5%.",
    "url": "https://finnhub.io/api/news?id=57e65b9d82ffaf11e0ab7631f7258f25ffb081a22d9b121213c88c42674c3714",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769090760,
      "headline": "Abbott Stock Slumps. The Nutrition Business Is a Drag on Earnings.",
      "id": 138204655,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Shares of  Abbott Laboratories  tumbled Thursday after the medical devices maker posted fourth-quarter earnings and sales that underwhelmed Wall Street.  The company said it expects full-year adjusted earnings in the range of $5.55 to $5.80 a share.  Abbott also is targeting full-year organic sales growth of between 6.5% to 7.5%.",
      "url": "https://finnhub.io/api/news?id=57e65b9d82ffaf11e0ab7631f7258f25ffb081a22d9b121213c88c42674c3714"
    }
  },
  {
    "ts": null,
    "headline": "Playing It Safe at 70 With $2.5 Million Is Likely To Backfire",
    "summary": "A 70-year-old investor with $2.5 million in blue-chip dividend stocks faces a question many retirees wrestle with: is playing it safe actually risky? On Reddit’s r/Bogleheads forum, one user questioned whether their early-70s father’s portfolio with just 10% in stocks was too conservative, noting it “seems just almost too conservative, where it’s almost at a ... Playing It Safe at 70 With $2.5 Million Is Likely To Backfire",
    "url": "https://finnhub.io/api/news?id=320a85bf58a307713306e2abbdda76898432fab2c841f75d4da8640f6ebb293c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769094485,
      "headline": "Playing It Safe at 70 With $2.5 Million Is Likely To Backfire",
      "id": 138205128,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "A 70-year-old investor with $2.5 million in blue-chip dividend stocks faces a question many retirees wrestle with: is playing it safe actually risky? On Reddit’s r/Bogleheads forum, one user questioned whether their early-70s father’s portfolio with just 10% in stocks was too conservative, noting it “seems just almost too conservative, where it’s almost at a ... Playing It Safe at 70 With $2.5 Million Is Likely To Backfire",
      "url": "https://finnhub.io/api/news?id=320a85bf58a307713306e2abbdda76898432fab2c841f75d4da8640f6ebb293c"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Johnson & Johnson: “One of the Best Pharmas There Is”",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. During the episode, Cramer discussed the company’s earnings and the following market reaction, as he stated: Alright, what do we make of these earnings from Johnson & Johnson? This morning, the pharma titan reported a healthy revenue beat and a very modest […]",
    "url": "https://finnhub.io/api/news?id=7e26b45e94ffbd2cd5f79b1cbde8051c1dd45c2c3bc82905bc90d4f4fb70b545",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769093985,
      "headline": "Jim Cramer on Johnson & Johnson: “One of the Best Pharmas There Is”",
      "id": 138204582,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. During the episode, Cramer discussed the company’s earnings and the following market reaction, as he stated: Alright, what do we make of these earnings from Johnson & Johnson? This morning, the pharma titan reported a healthy revenue beat and a very modest […]",
      "url": "https://finnhub.io/api/news?id=7e26b45e94ffbd2cd5f79b1cbde8051c1dd45c2c3bc82905bc90d4f4fb70b545"
    }
  },
  {
    "ts": null,
    "headline": "Is BMY's Deep Pipeline the Key to Its Next Growth Phase?",
    "summary": "BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.",
    "url": "https://finnhub.io/api/news?id=e30052199250baef2f56947ed670fb7e5683f6ed6f976ba74c3672c512b334a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769091300,
      "headline": "Is BMY's Deep Pipeline the Key to Its Next Growth Phase?",
      "id": 138205782,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.",
      "url": "https://finnhub.io/api/news?id=e30052199250baef2f56947ed670fb7e5683f6ed6f976ba74c3672c512b334a9"
    }
  },
  {
    "ts": null,
    "headline": "A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate Reality",
    "summary": "A dual-income couple approaching retirement with $1.2 million in savings and Social Security benefits faces a critical question: Will this be enough? The answer depends heavily on coordinating Social Security claims and structuring portfolio withdrawals. The Financial Snapshot Portfolio: $1.2 million in retirement savings Income source: Social Security benefits from dual earners Key challenge: Coordinating ... A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate Reality",
    "url": "https://finnhub.io/api/news?id=7a874664b4434bc3d08ad2f3e89c67ce6f29cff9b0ecc1312ca3ca1b07b210ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769090670,
      "headline": "A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate Reality",
      "id": 138204576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "A dual-income couple approaching retirement with $1.2 million in savings and Social Security benefits faces a critical question: Will this be enough? The answer depends heavily on coordinating Social Security claims and structuring portfolio withdrawals. The Financial Snapshot Portfolio: $1.2 million in retirement savings Income source: Social Security benefits from dual earners Key challenge: Coordinating ... A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate Reality",
      "url": "https://finnhub.io/api/news?id=7a874664b4434bc3d08ad2f3e89c67ce6f29cff9b0ecc1312ca3ca1b07b210ca"
    }
  },
  {
    "ts": null,
    "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
    "url": "https://finnhub.io/api/news?id=1a0efe0d2a9a9ecfcfff0e8f64c74b439c8f879b522874013117b946d029fa97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769090404,
      "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
      "id": 138204584,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
      "url": "https://finnhub.io/api/news?id=1a0efe0d2a9a9ecfcfff0e8f64c74b439c8f879b522874013117b946d029fa97"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: GE Aerospace orders surge, Procter & Gamble stock rises, Abbott tumbles",
    "summary": "A broader set of sectors will be represented when 35 more S&P 500 companies report earnings this week, including Netflix, Procter & Gamble, and Intel.",
    "url": "https://finnhub.io/api/news?id=2c6f158e213cf99e008a3817a55c075d6b66de568979edd20fc55183c57a1b0c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769087950,
      "headline": "Earnings live: GE Aerospace orders surge, Procter & Gamble stock rises, Abbott tumbles",
      "id": 138206841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "A broader set of sectors will be represented when 35 more S&P 500 companies report earnings this week, including Netflix, Procter & Gamble, and Intel.",
      "url": "https://finnhub.io/api/news?id=2c6f158e213cf99e008a3817a55c075d6b66de568979edd20fc55183c57a1b0c"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: GE Aerospace orders surge, Procter & Gamble and Abbott stocks dip",
    "summary": "A broader set of sectors will be represented when 35 more S&P 500 companies report earnings this week, including Netflix, Procter & Gamble, and Intel.",
    "url": "https://finnhub.io/api/news?id=0dbc79d78237b39df48b4d83b5c739ecbf08903a9480e2ddda046a19d5163bf3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769087950,
      "headline": "Earnings live: GE Aerospace orders surge, Procter & Gamble and Abbott stocks dip",
      "id": 138203808,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "A broader set of sectors will be represented when 35 more S&P 500 companies report earnings this week, including Netflix, Procter & Gamble, and Intel.",
      "url": "https://finnhub.io/api/news?id=0dbc79d78237b39df48b4d83b5c739ecbf08903a9480e2ddda046a19d5163bf3"
    }
  },
  {
    "ts": null,
    "headline": "FDA lays out new path to speed development of multiple myeloma drugs",
    "summary": "In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change that could accelerate cell therapies and other new medicines.",
    "url": "https://finnhub.io/api/news?id=7363b089812e65a05c9d5e44d2c6faa56186197442a7a97d0cb631c589035b77",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769081760,
      "headline": "FDA lays out new path to speed development of multiple myeloma drugs",
      "id": 138205783,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change that could accelerate cell therapies and other new medicines.",
      "url": "https://finnhub.io/api/news?id=7363b089812e65a05c9d5e44d2c6faa56186197442a7a97d0cb631c589035b77"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson reports 9.1% increase in sales for Q4 2025",
    "summary": "For the entire year, sales grew by 6% to $94.2bn, and full-year earnings per share registered at $11.03.",
    "url": "https://finnhub.io/api/news?id=80b05fb039331af0d02c49900381db3955240eb8088cd132e632037a43ed9a83",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769079797,
      "headline": "Johnson & Johnson reports 9.1% increase in sales for Q4 2025",
      "id": 138203092,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "For the entire year, sales grew by 6% to $94.2bn, and full-year earnings per share registered at $11.03.",
      "url": "https://finnhub.io/api/news?id=80b05fb039331af0d02c49900381db3955240eb8088cd132e632037a43ed9a83"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer's top 10 things to watch in the stock market Thursday",
    "summary": "The S&P 500 advanced this morning as Wall Street cheered signs of easing geopolitical tensions. Traders are also awaiting key inflation data.",
    "url": "https://finnhub.io/api/news?id=a020014ef53804cb955cd3b5a01cb07f030f9414918e6f77a73321210a6c3f47",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769071819,
      "headline": "Jim Cramer's top 10 things to watch in the stock market Thursday",
      "id": 138205257,
      "image": "https://image.cnbcfm.com/api/v1/image/108255380-17690331752026-01-21t220523z_286979253_rc2v5ja1vheb_rtrmadp_0_usa-stocks.jpeg?v=1769033262&w=1920&h=1080",
      "related": "JNJ",
      "source": "CNBC",
      "summary": "The S&P 500 advanced this morning as Wall Street cheered signs of easing geopolitical tensions. Traders are also awaiting key inflation data.",
      "url": "https://finnhub.io/api/news?id=a020014ef53804cb955cd3b5a01cb07f030f9414918e6f77a73321210a6c3f47"
    }
  },
  {
    "ts": null,
    "headline": "Resolve M Therapeutics exits from stealth",
    "summary": "Resolve M Therapeutics, Inc., the biotech aiming to build the world's first comprehensive pro-resolution platform for target ID, validation and drug discovery for the treatment of inflammatory diseases, has announced its exit from stealth. Resolve M was created through a strategic collaboration between Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., and General Inception, the global biotech company igniter, and reflects a bold com",
    "url": "https://finnhub.io/api/news?id=c7fee9d8e25182c5475e19293c021cc9da8d9d91875256977fca27e697e06865",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769068800,
      "headline": "Resolve M Therapeutics exits from stealth",
      "id": 138202438,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Resolve M Therapeutics, Inc., the biotech aiming to build the world's first comprehensive pro-resolution platform for target ID, validation and drug discovery for the treatment of inflammatory diseases, has announced its exit from stealth. Resolve M was created through a strategic collaboration between Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., and General Inception, the global biotech company igniter, and reflects a bold com",
      "url": "https://finnhub.io/api/news?id=c7fee9d8e25182c5475e19293c021cc9da8d9d91875256977fca27e697e06865"
    }
  },
  {
    "ts": null,
    "headline": "This 2.4%-Yielding Dividend King Remains As Healthy As Ever",
    "summary": "Johnson & Johnson had a strong year.",
    "url": "https://finnhub.io/api/news?id=f0956dde66e7481fd593b08b2d31859ed767859d4da85b3e681b647eb98ff5ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769065500,
      "headline": "This 2.4%-Yielding Dividend King Remains As Healthy As Ever",
      "id": 138201877,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson had a strong year.",
      "url": "https://finnhub.io/api/news?id=f0956dde66e7481fd593b08b2d31859ed767859d4da85b3e681b647eb98ff5ea"
    }
  },
  {
    "ts": null,
    "headline": "Housing Market’s Blue Christmas: Pending Sales Slide Most Since 2001",
    "summary": "The downturn comes at an interesting time: There are now 47% more sellers than buyers on the market, according to RedFin.",
    "url": "https://finnhub.io/api/news?id=e4abfe23618f060c6556d50fbeb910c423e853240e9f96c1e5f4288134fd9a4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769058060,
      "headline": "Housing Market’s Blue Christmas: Pending Sales Slide Most Since 2001",
      "id": 138203810,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The downturn comes at an interesting time: There are now 47% more sellers than buyers on the market, according to RedFin.",
      "url": "https://finnhub.io/api/news?id=e4abfe23618f060c6556d50fbeb910c423e853240e9f96c1e5f4288134fd9a4d"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Crushes Patent, Pricing Probs",
    "summary": "The company is vying to become the first among its healthcare peers to make $100 billion in annual revenue.",
    "url": "https://finnhub.io/api/news?id=971947ae35deed5c7aaa36c0437223d901199907bef43ba3a8a0a4c84cedaf7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769058060,
      "headline": "Johnson & Johnson Crushes Patent, Pricing Probs",
      "id": 138203277,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The company is vying to become the first among its healthcare peers to make $100 billion in annual revenue.",
      "url": "https://finnhub.io/api/news?id=971947ae35deed5c7aaa36c0437223d901199907bef43ba3a8a0a4c84cedaf7d"
    }
  },
  {
    "ts": null,
    "headline": "Is This Dividend King Stock a Buy After a Major Development?",
    "summary": "After a strong performance in 2025, Johnson & Johnson is starting the new year right.",
    "url": "https://finnhub.io/api/news?id=a30d729b439b93a63b1875fd5a31e94485d51f42ee4f303d286a107d45f6000a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769050200,
      "headline": "Is This Dividend King Stock a Buy After a Major Development?",
      "id": 138200755,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "After a strong performance in 2025, Johnson & Johnson is starting the new year right.",
      "url": "https://finnhub.io/api/news?id=a30d729b439b93a63b1875fd5a31e94485d51f42ee4f303d286a107d45f6000a"
    }
  }
]